epha.health
Feedback
New Case
Register
busy
1
Drugs
|
0
Findings
|
Advice

Pharmacological advice for alimemazin

plan
Print
Version 6.0.32 (Beta Preview)

Summary Summary info 89%

Pharmacokinetic 0%
Alimemazin
Scores -6%
QT time prolongation
Anticholinergic effects
Serotonergic effects
Adverse drug events -5%
Leukopenia
Hypotension
Photosensitivity

Variants ✨

For the computationally intensive evaluation of the variants, please choose the paid standard subscription.

medication Intended use

Alimemazine (also known as trimeprazine) is still used in some countries to prevent and relieve allergic conditions that cause itching and urticaria (itching with a vesicular rash). It is also used as a sedative and against nausea. It is taken orally as a tablet, juice, or drops. Alimemazin is used as an antihistamine, but its structure is also a neuroleptically effective phenothiazine. It binds to the histamine H1 receptors in the gastrointestinal tract, the skin, the airways and the blood vessels and thus prevents the occurrence of allergic symptoms. In addition, it has a sedative (calming) effect and works against nausea and vomiting.

undefined Pharmacokinetics info -0%

∑ Exposureaali
Alimemazin 1
Symbol (a): x-fold change in AUC
Legend (n.a.): Information not available

Since only alimemazin was entered without any further substances, no pharmacokinetic interactions can be detected.

Rating: The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability, half-life, and volume of distribution of alimemazin are unknown to us.

transmitter Serotonergic effects info -0%

Scores ∑ Points ali
Serotonergic Effects a 0 Ø
Symbol (a): Increased risk from 5 points.

Rating: According to our knowledge, alimemazin does not increase serotonergic activity.

transmitter Anticholinergic effects info -5%

Scores ∑ Points ali
Kiesel b 2++
Symbol (b): Increased risk from 3 points.

Recommendation: As a precaution, attention should be paid to anticholinergic symptoms, especially after increasing the dose and at doses in the upper therapeutic range.

Rating: Alimemazin modulates the anticholinergic system to a moderate extent. The risk of anticholinergic syndrome with this medication is rather low if the dosage is in the usual range.

electrocardiogram QT time prolongation info -1%

Scores ∑ Points ali
RISK-PATH c 0.5++
Symbol (c): Increased risk from 10 points.

Alimemazin can potentially increase QT time, but we do not know about torsades de pointes arrhythmias.

Other side effects General adverse effects info -5%

Side effects ∑ frequency ali
Leukopenia30.0 %30.0
Hypotension1.0 %+
Photosensitivity1.0 %+
Rash1.0 %+
Hyperprolactinemia1.0 %+
Dizziness1.0 %+
Dystonia1.0 %+
Insomnia1.0 %+
Agranulocytosis0.0 %0.0
Jaundice0.0 %0.0
Tabular extract of the most common side effects
Sign (+): side effect described, but frequency not known
Sign (↑/↓): frequency rather higher / lower due to exposure

Neurological
Neuroleptic malignant syndrome: alimemazin

Limitations Limitations

Based on your and scientific information, we assess the individual risk of undesirable side effects. The orange filled bars signal the basic potential of the drugs to cause this side effect. These recommendations are intended to advise professionals and are not a substitute for consultation with a doctor. In the restricted test version (alpha), the risk of all substances has not yet been conclusively assessed.

literature References

No literature information available.

epha.ch AG

Stadelhoferstrasse 40 8001 Zurich Switzerland
Github LinkedIn Facebook Twitter
kontakt@epha.ch

General

Imprint Data protection Terms of Use About us API

Languages

Deutsch English Français Italiano Español
Copyright © 2020 epha.ch - All rights reserved